odm-203
Small moleculeexperimental
Clinical trial activity
2 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Aug 24, 2017 (NCT03240445)
Timeline
2010s
- Jan 1, 2017
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
FLT1 inhibitor
- Fibroblast growth factor receptor 1INHIBITOR
FGFR1 inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05861947 | Phase 1 | May 31, 2023 | Aurigene Discovery Technologies |
| NCT03240445 | Phase 1 | Aug 24, 2017 | Orion Corporation, Quotient |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Aurigene Discovery Technologies | For profit | 1 | 1 | 1 | 2023 |
| Orion Corporation | For profit | 1 | 1 | 1 | 2017 |
| Quotient | For profit | 1 | 0 | 1 | 2017 |
3 organizations
Page 1 / 1